The company's BAMS technology combines immuno-enrichment of protein targets with MALDI to enable rapid, multiplexed analysis of proteins and proteoforms.
Two recently released preprints highlight new approaches to single-cell proteomics, including one making use of a modified version of Bruker's timsTOF Pro.
While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.
The firm is placing systems with at least two research collaborators and plans to target six to 10 early-access customers for its ProteoGraph platform in 2021.
In a recent study, the researchers examined the conditions under which carrier proteome-based single-cell workflows offered the best quantitative performance.
With the EUA, LabCorp is able to sell the test kit directly to consumers without a prescription, making it the first over-the-counter COVID-19 test in the US.
Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.
